{
  "openalex_id": "W3215203350",
  "doi": "https://doi.org/10.1093/neuonc/noab196.079",
  "title": "STEM-03. Oct4/Sox2 DRIVE AN IMMUNOSUPPRESSIVE GSC PHENOTYPE BY INDUCING T-REG EFFECTOR GENES VIA TGFBR2 SIGNALING",
  "abstract": "Abstract Solid malignancies, including GBM, contain small subsets of cells that display stem-like properties (i.e. glioma stem cells or GSCs) and act as key determinants of therapeutic resistance and tumor recurrence. Mechanisms of GSC immune escape are considered fundamental to clinical GBM growth and recurrence. GBM cells escape antitumor immunity by modifying the tumor microenvironment by secreting immune-suppressive factors and recruiting anti-inflammatory/pro-oncogenic cells (e.g. T-regulatory cells, M2-like macrophages). However, whether subsets of GSCs can mimic T-reg-like functions by expressing proteins associated with T-reg immune-suppression remains unknown. Single-cell RNA sequencing analysis of GBM neurospheres revealed a previously unrecognized Oct4/Sox2high/FOXP3- cell subpopulation with high expression of TGFb1, CD39, CD73, PD-L1, and Galectin-1, a gene expression fingerprint typically associated with T-reg cells and their immune suppressive functions within the tumor microenvironment. Bioinformatics analysis of public databases shows that the above-mentioned genes are enriched in the mesenchymal GBM subtype and highly correlated with CD44 and TGFb type II receptor (TGFBR2) expression in both clinical GBM and primary GSCs. Mechanistically, Oct4 and Sox2 were found to directly induce TGFBR2 transcription concurrent with chromatin architectural changes (i.e. heterochromatin-to-euchromatin transition) involving the TGFBR2 gene. Transgenic TGFBR2 expression increased neurosphere cell growth capacity, upregulated expression of T-reg-like effector genes and enriched for CD44+ GSCs. Functionally, neurospheres expressing transgenic Oct4/Sox2 or transgenic TGFBR2 possess increased immunosuppressive capacity, and pharmacological inhibition of TGFBR2 depleted CD44+ GSCs and reduced immunosuppression in Jurkat cell co-cultures. Taken together, we show that reprogramming events initiated by Oct4 and Sox2 induce a CD44+/FOX3P- GSC cell subset with a T-reg-like immunosuppressive transcriptional profile via a TGFBR2-dependent mechanism. This research provides the first description of such neoplastic cells in any malignancy and has high potential translational impact since targeting these tumor cell subsets and their immunosuppressive mechanisms may be critical to the successful development of GBM immunotherapies.",
  "authors": [
    {
      "display_name": "Amanda Johnson",
      "id": "A5031167345",
      "orcid": "https://orcid.org/0000-0002-3055-945X",
      "institutions": [
        {
          "id": "I2799853436",
          "display_name": "Johns Hopkins Medicine",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Amanda Johnson"
    },
    {
      "display_name": "Jack Korleski",
      "id": "A5043127223",
      "orcid": "https://orcid.org/0000-0003-3845-7869",
      "institutions": [
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        },
        {
          "id": "I2799853436",
          "display_name": "Johns Hopkins Medicine",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Jack Korleski"
    },
    {
      "display_name": "John Laterra",
      "id": "A5068043303",
      "orcid": "https://orcid.org/0000-0002-2983-5365",
      "institutions": [
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        },
        {
          "id": "I2799853436",
          "display_name": "Johns Hopkins Medicine",
          "country_code": "US",
          "type": "healthcare"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "John Laterra"
    },
    {
      "display_name": "Hernando LÃ³pez-Bertoni",
      "id": "A5038726786",
      "orcid": "https://orcid.org/0000-0001-6618-1092",
      "institutions": [
        {
          "id": "I2799853436",
          "display_name": "Johns Hopkins Medicine",
          "country_code": "US",
          "type": "healthcare"
        },
        {
          "id": "I145311948",
          "display_name": "Johns Hopkins University",
          "country_code": "US",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Hernando Lopez-Bertoni"
    }
  ],
  "publication_year": 2021,
  "publication_date": "2021-11-02",
  "type": "article",
  "cited_by_count": 1,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S106908163",
    "display_name": "Neuro-Oncology",
    "issn_l": "1522-8517",
    "issn": [
      "1522-8517",
      "1523-5866"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310311648"
  },
  "volume": "23",
  "issue": "Supplement_6",
  "first_page": "vi21",
  "last_page": "vi22",
  "open_access": {
    "is_oa": true,
    "oa_status": "bronze",
    "oa_url": "https://academic.oup.com/neuro-oncology/article-pdf/23/Supplement_6/vi21/41140484/noab196.079.pdf",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C2777933648",
      "display_name": "SOX2",
      "level": 4,
      "score": 0.74985594
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.7157949
    },
    {
      "id": "C2780932548",
      "display_name": "CD44",
      "level": 3,
      "score": 0.6785699
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.5912564
    },
    {
      "id": "C28328180",
      "display_name": "Stem cell",
      "level": 2,
      "score": 0.48262176
    },
    {
      "id": "C162746124",
      "display_name": "Neurosphere",
      "level": 5,
      "score": 0.47375947
    },
    {
      "id": "C2776107976",
      "display_name": "Tumor microenvironment",
      "level": 3,
      "score": 0.4622803
    },
    {
      "id": "C207701140",
      "display_name": "Homeobox protein NANOG",
      "level": 5,
      "score": 0.44889194
    },
    {
      "id": "C8891405",
      "display_name": "Immune system",
      "level": 2,
      "score": 0.44062722
    },
    {
      "id": "C95444343",
      "display_name": "Cell biology",
      "level": 1,
      "score": 0.43159378
    },
    {
      "id": "C55427017",
      "display_name": "Cancer stem cell",
      "level": 3,
      "score": 0.4152392
    },
    {
      "id": "C203014093",
      "display_name": "Immunology",
      "level": 1,
      "score": 0.37951267
    },
    {
      "id": "C148738053",
      "display_name": "Cellular differentiation",
      "level": 3,
      "score": 0.25047567
    },
    {
      "id": "C86339819",
      "display_name": "Transcription factor",
      "level": 3,
      "score": 0.22381413
    },
    {
      "id": "C1491633281",
      "display_name": "Cell",
      "level": 2,
      "score": 0.18968448
    },
    {
      "id": "C145103041",
      "display_name": "Embryonic stem cell",
      "level": 3,
      "score": 0.16152498
    },
    {
      "id": "C20875687",
      "display_name": "Adult stem cell",
      "level": 4,
      "score": 0.1426776
    },
    {
      "id": "C104317684",
      "display_name": "Gene",
      "level": 2,
      "score": 0.14015123
    },
    {
      "id": "C54355233",
      "display_name": "Genetics",
      "level": 1,
      "score": 0.10663214
    },
    {
      "id": "C107459253",
      "display_name": "Induced pluripotent stem cell",
      "level": 4,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T10336",
      "display_name": "Cancer Cells and Metastasis",
      "score": 0.7999
    },
    {
      "id": "T11297",
      "display_name": "Ferroptosis and cancer prognosis",
      "score": 0.7767
    },
    {
      "id": "T11765",
      "display_name": "Circular RNAs in diseases",
      "score": 0.7722
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1093/neuonc/noab196.079",
  "pdf_url": "https://academic.oup.com/neuro-oncology/article-pdf/23/Supplement_6/vi21/41140484/noab196.079.pdf",
  "retrieved_date": "2025-07-30T14:49:57.724536",
  "source_database": "OpenAlex"
}